Trial Information

Summary: Quality of Life study for patients with relapsing forms of Multiple Sclerosis who are transitioning from Rebif to Rebif-New Formulation

For persons currently using Rebif to control their Multiple Sclerosis, this study will evaluate their quality of life during the transition to a new investigational formulation of Rebif. Study medication will be provided at no cost to eligible subjects.

Patient Inclusion Criteria

  • Diagnosed with a relapsing form of Multiple Sclerosis
  • Currently taking Rebif injections three times per week for at least the past 6 months
  • Between ages 18-60

Patient Exclusion Criteria

  • Treatment with steroids within the past 3 months
  • Any other significant medical illness

Contact:

Kathy Stone, Research Nurse
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Telephone: 303-443-7229
Email:

Profile Page: Alpine Clinical Research Center, Boulder, CO

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:31:35 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA